Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong Wan

Showing results (491-500 of 526) with videos related to

Pageof 53
Sort By:
Gene|February 11, 2015
Replication the association of 2q32.2-q32.3 and 14q32.11 with hepatocellular carcinomaWei Chen, Mingquan Wang, Zhen Zhang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 17, 2011
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRKJürgen K Rockstroh, Jeffrey L Lennox, Edwin Dejesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 4, 2009
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infectionMartin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Plos One|March 17, 2009
FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformationEmilios Gemenetzidis, Amrita Bose, Adeel M Riaz, et al.
HIV Clinical Trials|August 2, 2012
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRKEdwin DeJesus, Jürgen K Rockstroh, Jeffrey L Lennox, et al.
Annals of Internal Medicine|June 6, 2022
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled TrialMatthew G Johnson, Amy Puenpatom, Pablo Andrés Moncada, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2007
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled studyMartin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
International Journal of Clinical and Experimental Pathology|January 23, 2020
Bioactivity of CD34+ cells in patients with acute-on-chronic liver failureYi-Chen Wu, Zhi-Hong Wan, Yi-Hui Rong, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 23, 2010
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II studyJose M Gatell, Christine Katlama, Beatriz Grinsztejn, et al.
Journal of the Pediatric Infectious Diseases Society|October 10, 2023
Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014Supattra Rungmaitree, Linda Aurpibul, Brookie M Best, et al.
Pageof 53

Showing results (491-500 of 526) with videos related to

Sort By:
Pageof 53
Gene|February 11, 2015
Replication the association of 2q32.2-q32.3 and 14q32.11 with hepatocellular carcinomaWei Chen, Mingquan Wang, Zhen Zhang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 17, 2011
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRKJürgen K Rockstroh, Jeffrey L Lennox, Edwin Dejesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 4, 2009
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infectionMartin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Plos One|March 17, 2009
FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformationEmilios Gemenetzidis, Amrita Bose, Adeel M Riaz, et al.
HIV Clinical Trials|August 2, 2012
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRKEdwin DeJesus, Jürgen K Rockstroh, Jeffrey L Lennox, et al.
Annals of Internal Medicine|June 6, 2022
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled TrialMatthew G Johnson, Amy Puenpatom, Pablo Andrés Moncada, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2007
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled studyMartin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
International Journal of Clinical and Experimental Pathology|January 23, 2020
Bioactivity of CD34+ cells in patients with acute-on-chronic liver failureYi-Chen Wu, Zhi-Hong Wan, Yi-Hui Rong, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 23, 2010
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II studyJose M Gatell, Christine Katlama, Beatriz Grinsztejn, et al.
Journal of the Pediatric Infectious Diseases Society|October 10, 2023
Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014Supattra Rungmaitree, Linda Aurpibul, Brookie M Best, et al.
Pageof 53